Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT01519804 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01519804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01519804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
September 30, 2015
Enrollment
108 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer